Naturally, NITE Will Help You Keep an Eye on NITE

Nightstar Therapeutics (NITE), a thinly-traded U.K.-based clinical-stage biotechnology company developing gene therapies for the treatment of currently untreatable retinal diseases, is surging back up to just below the key $22 breakout level.

Since its IPO nearly a year ago, in September 2017, NITE has largely flown under-the-radar as the stock's performance was rather uninspiring and the tepid volume a downright turnoff for most. 

But in early-July the stock saw some notable buying interest, helping propel the chart back over its major daily chart moving averages and base sideways the rest of this summer. 

Should we see further biotech sector gains into autumn, NITE would almost assuredly need to be monitored as an emerging small cap long idea in the sector with a few potential catalysts in September, to boot (though there is argument to be made that there are always potential catalysts on the horizon for small bios). 

Thus, we focus on the tangible: NITE above $22 makes for a sound long idea and a nice speculative watchlist play in a sector trying to resume its former glory from years ago as a market leader.